[Target selectivity of anticancer drugs].

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Context:

• Chemotherapy, while foundational in cancer treatment, often yields palliative effects rather than cures.
• Advances in understanding cancer genetics have led to targeted therapies with significant success in specific cases (e.g., imatinib for GIST).
• Tumorigenesis typically involves multiple genetic alterations, necessitating novel therapeutic strategies.

Purpose:

• To explore the evolution of anticancer drug development from traditional chemotherapy to molecularly targeted agents.
• To highlight the limitations of single-target therapies and advocate for multitargeted approaches.
• To introduce phase 0 clinical trials as a method for enhancing drug selectivity and patient stratification.

Summary:

• Current anticancer drug development is shifting from broad-spectrum chemotherapy towards agents targeting specific molecular pathways.
• The complexity of cancer, driven by multiple genetic changes, suggests that multitargeted therapies may offer superior efficacy.
• Phase 0 clinical trials represent a promising avenue for improving the precision of anticancer drug selection and patient matching.

Impact:

• This research informs the development of more effective and personalized cancer treatments.
• It emphasizes the need for a deeper understanding of tumor molecular profiles to guide therapeutic decisions.
• The findings support the integration of innovative trial designs like phase 0 studies to accelerate the discovery of optimal cancer therapies.